Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sorin Brener

Interventional Cardiology Brooklyn, NY Medical Doctor

NPI 1104930338 CMS profile 322816

506 6Th St, Brooklyn, NY 11215

Open in the dashboard

General payments

$166,239

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$20,275

7 holdings reported · through program year 2025

Research they led as principal investigator

$5,500 paid to institutions, not to them · program year 2020

Through program year 2025, Sorin Brener of Brooklyn, NY is reported in the CMS Open Payments database as having received $166,239 across 239 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,500 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $20,275 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,875 11
2024 General $12,202 21
2023 General $25,372 42
2022 General $20,211 36
2021 General $23,030 33
2020 General $24,985 27
2019 General $47,563 69
2025 Ownership $8,325 1
2024 Ownership $3,600 1
2023 Ownership $2,050 1
2022 Ownership $1,450 1
2021 Ownership $1,450 1
2020 Ownership $1,700 1
2019 Ownership $1,700 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sorin Brener
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sorin Brener were reported at $12,875. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sorin Brener Interventional Cardiology median Middle half National median
2019 $47,563 $1,097 $329–$3,048 $163
2020 $24,985 $473 $161–$1,480 $114
2021 $23,030 $677 $233–$1,827 $132
2022 $20,211 $978 $333–$2,724 $149
2023 $25,372 $1,136 $382–$2,986 $160
2024 $12,202 $1,181 $395–$3,326 $164
2025 $12,875 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $114,044 107 payments
  2. Abbott Laboratories $42,544 80 payments
  3. Medtronic Vascular, Inc. $5,331 16 payments
  4. Contego Medical, Inc $2,000 1 payment
  5. Boston Scientific Corporation $542 8 payments
  6. Abiomed $440 7 payments
  7. Edwards Lifesciences Corporation $404 4 payments
  8. Medtronic, Inc. $355 6 payments
  9. Siemens Medical Solutions USA, Inc. $168 2 payments
  10. Biotronik Inc. $124 1 payment
  11. Other $289 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,250 37 payments
  2. Consulting Fee $40,816 37 payments
  3. Travel and Lodging $16,894 44 payments
  4. Food and Beverage $10,261 119 payments
  5. Honoraria $2,000 1 payment
  6. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. BRILINTA $96,306 87 payments
  2. XIENCE V $23,066 22 payments
  3. FARXIGA $17,724 19 payments
  4. XIENCE SKYPOINT $12,875 11 payments
  5. CoreValve Evolut $5,331 16 payments
  6. DRAGONFLY OPSTAR $1,894 14 payments
  7. XIENCE XPEDITION $1,000 1 payment
  8. MITRACLIP $671 4 payments
  9. Tricuspid Valve Repair System $500 1 payment
  10. Impella $440 7 payments
  11. Other $3,943 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

308

Median for Cardiology: 2,533

Drug cost

$83,533

Median for Cardiology: $485,213

Branded share of claims

38%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 45 $54,854
Eliquis Apixaban Brand 17 $25,177
Metoprolol Succinate Generic 45 $1,038
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 11 $480
Atorvastatin Calcium Generic 40 $473
Clopidogrel Clopidogrel Bisulfate Brand 44 $466
Pantoprazole Sodium Generic 17 $374
Furosemide Generic 20 $244
Lisinopril Generic 35 $219
Amlodipine Besylate Generic 21 $111

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$21,903

Medicare's payments for the services billed

Medicare patients

82

Average age 78

Services billed

203

47 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Diabetes 62%
Heart failure 61%
Chronic kidney disease 56%
Arthritis 56%
Atrial fibrillation 52%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $31
$31 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record